To date, three loci have been validated to confer susceptibility to inflammatory bowel disease (IBD): the CARD15/NOD2 gene, the discs large homolog 5 gene (DLG5), and the IBD5 locus on 5q31 (IBD5). We have explored the possibility that these loci may also be associated with susceptibility to two other chronic inflammatory diseases, multiple sclerosis (MS) and systemic lupus erythematosus (SLE). As the CARD15 risk alleles had previously been assessed in our collection of 496 MS trios, we focused our efforts on the DLG5 risk allele and the IBD5 risk haplotype (IBD5 risk ) for MS. While there is no evidence of association within our MS sample with either of these polymorphisms, screening of 1027 subjects with SLE suggests that IBD5 risk may have a modest contribution to disease risk in the subset of SLE subjects without lupus nephritis. In addition, a pooled analysis of existing published and unpublished data in 1305 cases of SLE genotyped for the CARD15 risk alleles suggests that only the CARD15 908R IBD risk allele may have a strong effect on risk of SLE. Our data, therefore, suggest that both the CARD15 gene and the IBD5 locus may have a role as general susceptibility loci for certain common, genetically complex inflammatory diseases.
Introduction
There has been much progress in the field of genetic susceptibility to inflammatory bowel disease (IBD) over the past few years. Alleles or haplotypes within three different loci outside of the human leukocyte antigen (HLA) locus have been associated with increased risk of IBD or one of its two major forms, Crohn's Disease (CD) and Ulcerative Colitis (UC). Three different mutations were first described in the caspase recruitment domain family member 15/nucleotide oligomerization binding 2 (CARD15/NOD2) gene on 16q21.1 as being associated to CD [1] [2] [3] and later confirmed. [4] [5] [6] [7] [8] [9] [10] [11] [12] A risk haplotype within the IBD5 locus was then described on 5q31 13 and later confirmed to be associated with increased risk to CD, [14] [15] [16] [17] and potentially to a subgroup of UC. 14, 18 Further refinement of this risk haplotype (IBD5  risk ) is ongoing, and a single causative allele within the IBD5 risk haplotype has not yet been definitively identified. 19, 20 Finally, the R30Q variant of the discs, large homolog 5 (DLG5) gene was associated with risk for IBD on 10q22.3, 21 and this association has been replicated in both Japanese subjects 20 and subjects of European ancestry. 22 Although the exact mechanisms by which these three susceptibility loci influence disease susceptibility is unknown, it is possible that these same variants have a role to play in other chronic inflammatory diseases such as multiple sclerosis (MS) and systemic lupus erythematosus (SLE). The existence of alleles affecting susceptibility to multiple inflammatory disorders in humans is now well documented. Within certain families, different individuals can present with different inflammatory processes such as inflammatory bowel disease (IBD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and/or other diseases. [23] [24] [25] [26] [27] [28] Epidemiological studies of IBD and MS have sometimes demonstrated the concurrence of these two diseases. 29 An MS prevalence rate of 0.5-1% in cases of IBD is more than would be expected by chance alone, 30, 31 and the association appears to be stronger with the UC subset of IBD. 32, 33 However, this association has not been a consistent finding. 23, 34 Given the role of genetic susceptibility in both diseases, 29, 35 it is possible that they may share susceptibility loci. The role of the HLA locus has been documented in both diseases, although different haplotypes appear to be associated with each disease. [35] [36] [37] In addition, a review of linkage scans performed in IBD and MS has shown that there are five chromosomal regions with evidence of overlapping statistically 'suggestive' linkage peaks outside of the HLA locus. 38 However, the limited statistical power of these linkage studies precludes making any definitive statements regarding loci of shared genetic susceptibility at this time. The 5q31 region that was identified in our original IBD susceptibility linkage scan was not identified in the latter study, but it is close to the third highest linkage peak (MLS ¼ 2.18) in the recent high resolution linkage scan in 730 multiplex MS pedigrees. 39 This makes IBD5 risk a particularly interesting candidate to explore in the context of MS susceptibility.
In contrast, very little is known about the concurrence of IBD and SLE. Nevertheless, as with MS and IBD, there is evidence for a shared linkage region between IBD and SLE outside of the HLA locus; the 16q12-13 region has been linked to SLE [40] [41] [42] and contains the CARD15 gene variants associated with CD. [1] [2] [3] This overlap in linkage and association studies has, so far, led to two additional association studies. Both a study of 189 Spanish SLE patients and a study of 188 Hong Kong Chinese SLE patients failed to show association between these three CARD15 alleles and SLE. 43, 44 However, being only modestly powered, neither study was able to unambiguously rule out a role for these three alleles in susceptibility to SLE.
We therefore set out to specifically address whether known IBD-associated genetic variants play a role in susceptibility to MS and/or SLE: we genotyped the three CARD15 coding polymorphisms {R702W (rs2066844) in exon 3, G908R (rs2066845) in exon 7, and the insertion 3020insC in exon 10 (Hugot SNP13)}, the DLG5 R30Q polymorphism (rs1248696) and the IBD5 risk surrogate marker rs11739135 in subjects with MS and SLE.
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Results
We screened the validated IBD risk allele in DLG5 and the IBD5 risk haplotype (IBD5 risk ) in our collection of MS samples (Table 1 ) but found no evidence of association with susceptibility to MS ( Table 2 ). The CARD15 IBD risk alleles had already been genotyped in the majority of these samples as part of another project and were therefore not investigated as part of this effort. The prior investigation demonstrated no evidence of association between these CARD15 alleles and susceptibility to MS. 45 In the SLE screening sample ( Table 1 , SLE-A), of the five variants tested, only the 'G' allele of rs11739135, a surrogate for the IBD5 risk haplotype, 13 showed suggestive Each of the listed alleles is the risk allele for these polymorphisms. The CARD15 polymorphism labels correspond to: rs2066844/R702W, rs2066845/G908R , HUGOT_SNP13/3020insC. 'T' stands for transmitted alleles, and 'U' stands for untransmitted alleles in the TDT analysis.
The role of IBD susceptibility loci in MS and SLE PL De Jager et al evidence of association with a diagnosis of SLE (P ¼ 0.01) ( Table 2 ). The 'G' allele is overtransmitted in the SLE trios, just as it is in the CD and UC trios. 13, 14 In order to confirm this observation, we genotyped rs11739135 in several other collections of SLE samples from Europe and the United States (Table 1 ; SLE-B to -F), but a pooled analysis of individual Z-scores failed to demonstrate statistically significant overtransmission of the rs11739135 'G' allele (P ¼ 0.49). The association of IBD5 risk with susceptibility to SLE has therefore not been replicated in an independent sample collection. When all subjects (samples SLE-A to -F) are pooled, a MantelHaenszel pooling of the odds ratios produces an OR of 1.06 for IBD5 risk in SLE susceptibility (95% confidence interval (CI) 0.96-1.18; P-value ¼ 0.086). 46 Given the positive result in screening the SLE-A population with rs11739135, two stratified analyses of IBD5 risk in the SLE-A population were performed using (1) the known SLE risk haplotype HLA DR3 and (2) a diagnosis of lupus nephritis (Table 3) . Only a diagnosis of SLE in the absence of nephritis was associated more closely to IBD5 risk (P ¼ 0.002) than the phenotype of susceptibility to SLE (P ¼ 0.010) ( Tables 2 and 3 ). The same phenotype data were available in the SLE-B and SLE-F sample sets, and again there was a slight trend was for association in the subgroup of subjects, which do not have nephritis. However, this result was not statistically significant (P ¼ 0.27; Table 3 ) in the pooled analysis of the SLE-B and SLE-F samples; when individual Z-scores of sample collection subsets without nephritis are pooled (SLE-A, -B, and -F), we do report a suggestive association of the rs11739135 'G' allele, a surrogate marker for IBD5 risk with risk of SLE in the absence of nephritis (P ¼ 0.018).
As two previous studies had explored the role of the CARD15 alleles in SLE, we pooled data collected from our study of population SLE-A with data collected in a population of Spanish subjects with SLE 43 and a population of Hong Kong Chinese subjects affected with SLE 44 as well as an independently generated data set of genotypes from a collection of American SLE subjects (Table 4) . A Pearson w 2 goodness-of-fit test reveals no evidence of genetic heterogeneity among the four populations in terms of the pooled allele frequencies of the CARD15 risk alleles (P ¼ 0.52;
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). However, the allele frequency is clearly less in the Chinese population, and this population, therefore, provides little data on the association of any CARD15 risk allele with SLE. A Mantel-Haenszel pooling of the odds ratios (OR) 46 was performed for each allele and for the combination of all three CARD15 risk alleles. While the presence of any one of the three CARD15 risk alleles produced a very modest OR of 1.08 (95% CI 0.97-1.19), there is evidence that the 908R risk allele has a strong effect on risk of SLE -OR of 2.01 (95% CI 1.01-4.03; P ¼ 0.022) -while the other two alleles have no suggestive or significant evidence of association (Table 4) .
Discussion
While the DLG5 risk allele and IBD5 risk haplotype do not appear to have a strong effect on susceptibility to MS, IBD risk alleles appear to have an effect in SLE. Pooled analysis of all samples -susceptibility to SLE without lupus nephritis SLE-A, B, F P ¼ 0.018
Abbreviations: SLE, systemic lupus erythematosus;DSP, discordant sibpair. As described in the Materials and methods section, these analyses of combined sample collections were performed by calculating a separate Z-score for each trio and sib-pair sample collection; the Z-scores were then added together; and a one-tailed P-value was derived from the Zscore. Only the rs11739135 'G' allele (the surrogate marker for IBD5 risk ) was tested for association in the replication sample; this is the allele associated to IBD and to SLE in our exploratory sample. The presence or absence of nephritis was only available for samples in collections SLE-A, SLE-B, and SLE-F. Results meeting our predetermined threshold of suggestiveness have been highlighted in bold.
Specifically, the CARD15 908R allele appears to have a strong effect on risk to SLE (OR 2.01; 1.01-4.03), whereas the IBD5 risk haplotype may potentially have a weak effect (OR 1.06; 0.96-1.18). Despite genotyping large numbers of subjects affected with SLE, our results are not definitive: our replication effort for IBD5 risk only trended towards confirmation of the association, particularly in the subset of subjects with SLE who do not have lupus nephritis (Table 3) , and the CARD15 908R association in the pooled analysis just fails to achieve statistical significance once the testing of multiple hypotheses is accounted for using a Bonferroni correction. Nonetheless, these data offer strongly suggestive evidence that IBD5 risk and CARD15 908R may play a role in SLE susceptibility. In both cases, large collections of samples will be needed to confirm these results since the effect of IBD5 risk is quite weak in SLE and the CARD15 908R allele is of modest frequency. The association of CARD15 908R to risk of SLE is particularly intriguing given the prior suggestive linkage of the 16q12-13 region containing CARD15 to SLE susceptibility. [40] [41] [42] However, given the rarity of the CARD15 908R allele, its putative effect on SLE susceptibility is unlikely to completely explain these linkage results; additional CARD15 alleles may therefore be associated with SLE susceptibility. Another gene in 16q13, OLF1/EBF-associated zinc finger gene (ZNF423/ OAZ), displays modest evidence of association with susceptibility to lupus nephritis in a Chinese population and may contribute to the linkage peak as well. 47 The ZNF423 result awaits replication but is likely to be independent of our CARD15 908R observation since the two genes are separated by 966 kb of DNA and the maximum r 2 between any two SNPs from these genes is 0.144 (between rs2066845 in CARD15 and rs1344531 in ZNF423) in the current HapMap data 48 (http:// www.hapmap.org/index.html.en).
A critical question for association studies is the statistical power that is available to address the hypotheses being pursued. This information is useful in interpreting the meaning of a negative result. In our study, IBD5 risk has been assessed with 82.3% power in the MS sample of 496 trios given its allele frequency of 0.41, a reported odds ratio (OR) of 1.3 in CD, 14 a multiplicative model of disease and an alpha of 0.05 (the threshold of suggestiveness in our study)(Purcell et al. 49 ; http:// statgen.iop.kcl.ac.uk/gpc/). Thus, we have reasonable power to exclude an effect on risk 41.3 for IBD5 risk in MS but cannot rule out a more modest role for this haplotype. In terms of DLG5, the risk allele is found at a frequency of 0.10 in our MS sample and 0.16 in the SLE sample and was not associated with either disease. The effect of this variant on risk of CD has been most recently estimated to be an OR of 1.5 in all subjects, and this OR is largely due to male subjects (OR 2.5) since female subjects with CD had an OR of 1.0. 50 The MS sample of 496 trios, therefore, has 83.1% power to assess the DLG5 risk allele given a multiplicative model of disease and an alpha of 0.05 (Purcell et al.
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; http://statgen.iop.kcl. ac.uk/gpc/). More specifically, it has 98.7% power using the same parameters in an analysis restricted to the 175 Graham and Behrens, data acquired independently of this study -these cases from the USA include collections SLE-E and F as well as additional subjects collected in the USA by the same center. These CARD15 SNPs were genotyped using the ABI-3700 platform in the USA collection of samples. The minor allele frequencies of these alleles in the parents of the trios are: rs2066844 -0.07, rs2066845 -0.02, and Hugot_SNP13 -0.03. The allele frequencies of the parents of trios from the SLE-A collection are presented in Table 2 . Results meeting our threshold of statistical suggestiveness are highlighted in bold.
trios with male probands found in our collection. Given the preponderance of the role of DLG5 risk allele in male subjects, we performed a gender-stratified analysis, but this effort also failed to demonstrate evidence of association between the DLG5 risk allele and MS in either male or female probands (data not shown). In the SLE sample of 254 trios, we have 70% power to assess the DLG5 risk allele in the overall sample given a multiplicative model of disease and an alpha of 0.05 (Purcell et al. 49 ; http://statgen.iop.kcl.ac.uk/gpc/). However, there were only 26 SLE trios with a male proband, and, therefore, we have insufficient power to address the male-specific association using the same parameters. Thus, we can say that we have reasonable power to exclude the DLG5 risk allele from being a risk factor in MS; on the other hand, our analysis in SLE leaves open the question of a male-specific effect of the DLG5 risk allele given the small number of trios with male probands in our screening sample.
Looking more closely at CARD15 908R in SLE, we can take its OR as a rough estimate of genotype risk ratio (GRR), and an OR of 2 for CARD15 908R in SLE is similar to the GRRs of 2-4 observed for heterozygotes carrying different CARD15 risk alleles in CD (reviewed in Eckmann and Karin 51 ). These three CARD15 CD risk alleles have also been associated with psoriatic arthritis (PsA) and graft-versus-host disease (GvHD) in small subject samples. 52, 53 Yet, other studies describe associations of additional clinical phenotypes with different CARD15 alleles: for example, Blau syndrome is a rare autosomal dominant disorder consisting of granulomatous arthritis, uveitis, skin rash, and campylodactyly that is associated with CARD15 alleles that are not involved in susceptibility to CD. 54 Furthermore, some of the Blau Syndrome-associated alleles may have a role in early onset sarcoidosis (EOS). 55 So far, only one sporadic case of Blau syndrome has been reported to have a CD-associated risk allele; interestingly, this individual is a compound heterozygote of CARD15 908R and CARD15 334Q , one allele associated with Blau syndrome.
CARD15
908R is the allele with which we have observed an association to SLE susceptibility and is also the only one of the CD-associated alleles found to be enriched in the subset of subjects with IBD who also have spondylarthritis. 57 CARD15 908R has therefore been associated with a broader range of inflammatory diseases than the other two CD-associated alleles, CARD15 702W and CARD15 3020insC . CARD15 908R is found in one of the leucine-rich repeat (LRR) domains of CARD15; these LRR domains are suspected to mediate the recognition bacterial products and to initiate the activation of CARD15. However, their exact role and mechanism of action remain unclear (reviewed in Strober et al. 58 ), and there is currently no available functional data on CARD15 908R specifically. Nonetheless, functional analyses are beginning to demonstrate differences between the effects of different CARD15 risk alleles: a CARD15 684W homozygote had an in vitro response to Helicobacter Pylori peptidoglycan that was similar to that of control subjects while CARD15 3020-Cins homozygotes had a severely depressed response to the same stimulus. 59 On the other hand, other responses, such as IL-8 and TNFb secretion, to bacterial products appear to be similar among the different groups of compound CARD15 risk heterozygotes. 60 Given this phenotypic and functional heterogeneity in CARD15 alleles, it is possible that, among the three risk alleles studied here, only the CARD15 908R allele may be involved in increased susceptibility to both CD and SLE. When we exclude the Hong Kong population in which the CARD15 alleles are very rare, we have now assessed 1117 subjects with SLE in our pooled analysis (Table 4) and therefore have 96.5% power to identify a risk allele with a frequency of 0.02 (lowest minor allele frequency observed in our European populations for any of the CARD15 polymorphisms) and a genotype risk ratio of 2.0 given a multiplicative model of disease and an alpha of 0.05 (Purcell et al. 49 ; http://statgen.iop.kcl. ac.uk/gpc/). These parameters are based on the effect size and frequency of CARD15 alleles in CD. 51 Thus, we are fairly confident that the other CDassociated CARD15 alleles (702W and 3020insC) have no strong role in SLE, unless their effect on risk of disease is more modest than the one seen with CD. However, we have not addressed whether other, non-CD associated CARD15 alleles may also have role in SLE.
The case for CARD15 908R to have a role in susceptibility to SLE is strongly suggestive (P ¼ 0.022), but the case for IBD5 risk is weaker. We failed to replicate our original observation of association, yet we can say that the combined replication sample set of 494 trios and 279 discordant sib pairs with SLE provides over 90% power only to detect an OR of 1. risk may thus be a severity allele for IBD, explaining its low OR in analyses of IBD susceptibility. Its putative role in SLE may be similarly restricted to a subgroup of subjects with a particular phenotypic profile. In the sample collections surveyed, the association of IBD5 risk with SLE is strongest in those subjects who did not have lupus nephritis, one of only two SLE subtypes tested in our exploratory sample. Once all relevant samples are considered (Table 3) , the association with this less severe disease subtype remains suggestive (P ¼ 0.018). Given the different sources of samples used in our replication effort, local differences in the diagnosis and recruitment of SLE cases and fluctuations in the representation of this particular disease subtype may be one reason why our replication effort was unsuccessful. Future focused analyses of IBD5 risk targeted at subjects with SLE that do not have lupus nephritis in other collections will certainly help to address the role of IBD5 risk in SLE. An interesting model is emerging for chronic inflammatory diseases: they appear to share different combinations of susceptibility alleles, which may exert effects of different strengths in different diseases. So far, there is good evidence for the involvement of the PTPN22 620W allele in autoimmune thyroiditis (AIT), rheumatoid arthritis, SLE, and type 1 diabetes (T1D) but not MS and IBD (reviewed in Siminovitch 61 and De Jager et al. 62 ), 
Materials and methods
Human subjects and study design Our screening populations were drawn from the United Kingdom and consisted of 496 MS trios (MS-A) and 254 SLE trios (SLE-A) ( Table 1 ). All affected subjects met the McDonald criteria 64 for a diagnosis of MS or the American College of Rheumatology (ACR) criteria 65, 66 for a diagnosis of SLE, respectively. All individuals gave written informed consent for genetic analysis. The study has ethical approval from the Anglia and Oxford Multicentre Ethics Committee (MS samples) and the London Multicentre research Ethics Committee (SLE samples).
For both its MS and SLE portions, our study was designed to have two discrete phases (a screening phase and a replication phase) with strict criteria for progression of a finding from the screening to the replication phase: we designated a P-value (uncorrected for multiple hypotheses testing) of 0.05 as a threshold of statistical suggestiveness of association that must be met for a result to be considered in the replication effort. Likewise, secondary analyses were only performed for those alleles demonstrating a main effect that met our criterion of statistical suggestiveness. The secondary analyses considered for this study included stratification of a suggestive result using the well-validated phenotype of nephritis in SLE and the presence of an HLA risk allele for MS (HLA DR2) or SLE (HLA DR3).
Given the suggestive association seen in the SLE screen, we assembled a replication sample by pooling several different American and European collections of SLE samples (Samples SLE-B to -F; Table 1 ); the replication sample consists of a total of 494 trios and 279 discordant sibling pairs. For samples SLE-B to -F, all affected subjects met the American College of Rheumatology (ACR) criteria 65, 66 for a diagnosis of SLE. All individuals gave written informed consent for genetic analysis. The study has ethical approval the London Multicentre research ethics committee (SLE-B and C), the ethical committees of the University of Helsinki and Kuopio hospital (SLE-D), and the University of Minnesota Human Subjects Review Board (SLE-E and F). A Pearson w 2 goodness-of-fit test of the rs11739135 allele data reveals no evidence of genetic heterogeneity among these different populations or with the original population (P ¼ 0.42). 46 Genotyping All five SNPs -rs2066844, rs2066845, CARD15 Hugot SNP13, 2 rs1248696, and rs11739135 13 -were genotyped using a Sequenom MassArray MALDI-TOF platform as described elsewhere. 67 Each of these five assays produced genotypes for at least 97% of samples, did not deviate from Hardy-Weinberg Equilibrium (HWE) and displayed no more than 0.5% Mendelian errors. HWE was assessed using a w 2 statistic in the control subjects and in the affected subjects; we expressed this statistic as a P-value, with Po0.001 being considered as evidence of disequilibrium. In the MS screening sample, the majority of cases had been previously genotyped for the three CARD15 risk alleles and shown not to be associated with susceptibility to MS; 45 they were therefore not genotyped as part of this screen of MS samples. The three CARD15 risk alleles arose independently on the same haplotype the three CARD15 risk alleles arose independently on the same haplotype.
14 In our dataset, they were not in strong linkage disequilibrium in either the MS or the SLE samples (maximum r 2 between two of these SNPs was 0.44 in the larger MS sample). Thus, these alleles do not function as surrogates for each other and need to be assessed independently.
Statistical analysis
The data were analyzed using the Transmission Disequilibrium Test (TDT) 68 as implemented in TRANS-MIT. 69 Individual TDT and sib TDT tests were run on each replication sample (SLE-B to -F) using TRANS-MIT, 69 and the results were combined using a Z-score. Specifically, the number of risk alleles transmitted in trios or found in the discordant sib pairs was reformatted as a mean or expected count (E T and E C ), observed count (O T and O C ), and variance (var T and var C ). A combined Z-score was then calculated by summation as
. A MantelHaenszel approach was used to calculate a pooled odds ratio (OR). 46 
